Skip to content

AcrySof™ IQ PanOptix™ Toric UV IOL TFAT60 (REF TFAT60.195)Recalls & reported problems

Alcon Laboratories, Inc. · AcrySof® IQ PanOptix® Toric Trifocal intraocular lenses (IOLs) are ultraviolet absorbing foldable multifocal IOLs · Class 3 · Implant

All models of AcrySof IQ PanOptix Toric UV IOL (120)

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 00380652420280), received between Oct 27, 2021 and Oct 27, 2021 — classified as 1 injury.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem1

Patient problems

  • Blurred Vision1
  • Visual Impairment1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryOct 27, 2021Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    A FACILITY REPRESENTATIVE REPORTED THAT FOLLOWING IMPLANTATION OF AN INTRAOCULAR LENS PATIENT EXPERIENCED CLOUDY VISION, FILM, BLURRED VISION, SEVERE GLARE. THE LENS WAS EXCHANGED WITH A NEW ONE IN A SECONDARY PROCEDURE. ADDITIONAL INFORMATION WAS REQUESTED AND RECEIVED REPORTING THAT IN SURGEONS OPINION MECHANICAL COMPLICATION, SEVERE GLARE AND BLURRED VISUAL ACUITY CAUSED OR CONTRIBUTED TO THE EVENT. THERE WAS NO PATIENT HARM.

    Patient problems: Blurred Vision; Visual Impairment

    MAUDE report 12703513 ↗

Other Lens, multifocal intraocular devices

All Lens, multifocal intraocular devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page